Design, reporting, and research focus of neurology and psychiatry drug trials (2020-2023): a registry-based meta-epidemiological study using ClinicalTrials.gov and NLP.
Trials · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansClinical Trials as TopicMental DisordersNatural Language ProcessingNeurologyPsychiatryPsychotropic DrugsRegistriesResearch DesignAlzheimer’s diseaseCNS drug trialsClinical trial registriesClinicalTrials.govDepressionMultiple sclerosisNatural language processing (NLP)PainParkinson’s diseaseResults reportingSchizophreniaTrial designParkinson’s DiseaseTrial DesignClinicaltrials.govNatural Language Processing (Nlp)Clinical Trial RegistriesResults ReportingCns Drug Trials
Come citare questo studio
Doneva SE, Sick B, Ellendorff TR, Goldman JP, Reich DS, Hemkens LG, Schneider G, Ineichen BV. (2026). Design, reporting, and research focus of neurology and psychiatry drug trials (2020-2023): a registry-based meta-epidemiological study using ClinicalTrials.gov and NLP.. Trials. DOI: 10.1186/s13063-026-09909-8
Consulta la pubblicazione originale ↗